Fathom Therapeutics, a biotech firm leveraging quantum chemistry and AI, has successfully closed an oversubscribed $47 million Series A financing round. The funding was led by Sutter Hill Ventures and will advance the company's mission to redesign the drug discovery process. This capital infusion marks a significant milestone for the New York-based company, formerly known as Atommap Corp., as it scales its innovative platform.
A New Paradigm in Drug Discovery
Traditional drug discovery often relies on static models of proteins, which limits its effectiveness in predicting real-world interactions. Fathom Therapeutics challenges this by simulating the dynamic motion of proteins within living cells through its Microcosmos platform. This innovative approach allows for the design of small molecules that can precisely reshape protein behavior for a desired therapeutic effect.
The company's proprietary algorithms accelerate the modeling of protein dynamics by a factor of 10,000 without compromising scientific accuracy. Microcosmos has already demonstrated its potential by generating potent and selective drug candidates against a previously "undruggable" target in just six weeks. These candidates are now being optimized for clinical advancement, showcasing the platform's rapid and effective discovery capabilities.
Investor Confidence and Strategic Vision
Investor confidence is high, with Keith Loebner of Sutter Hill Ventures highlighting the team's vision to rethink how machines understand molecules. He praised the company's unique combination of physics and machine learning, which moves the frontier in computational drug design. This strong backing validates Fathom's approach and its potential to transform molecular design into new medicines for patients.
The new capital will be instrumental in scaling Fathom's lab-in-the-loop capabilities and expanding its internal discovery programs for high-impact diseases. The company plans to build a "flywheel" for creating novel small molecule medicines that were previously considered impossible to develop. This strategic expansion is supported by an active pipeline and multiple external discovery partnerships already in place.
Bolstering Leadership and Expertise
To guide its next phase of growth, Fathom has made key additions to its leadership team. Mandana Honu, a strategic advisor to Sutter Hill Ventures, has been appointed as the new Chief Business Officer. Additionally, seasoned biotech entrepreneur Diala Ezzeddine has joined the board of directors, bringing over two decades of industry experience.
The company has also established a distinguished Scientific Advisory Board to provide strategic guidance on its drug design and pipeline development. This board includes industry veterans such as Ian Taylor, former Chief Scientific Officer of Arvinas, and other experts in biology and technology. Their collective expertise will be crucial in accelerating the journey from initial concept to regulatory approval for new therapies.
With a substantial $47 million in new funding and a strengthened leadership team, Fathom Therapeutics is poised to accelerate its pioneering work in drug discovery. The company's Microcosmos platform represents a significant leap forward, promising to unlock new treatments for challenging diseases. This strategic investment and expansion of expertise solidify Fathom's position as a key innovator in the biotech landscape.